Tasly Pharmaceutical Group Co. Ltd. Class A 600535

SSE · China · Health Technology

CNY 14.00+0.26 (+1.89%)

Market closed· Sep 30, 2026, 7:00 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Tasly Pharmaceutical Group Co. Ltd. Class A 600535

SSE · China · Health Technology

CNY 14.00+0.26 (+1.89%)

Market closed· Sep 30, 2026, 7:00 AM UTC· CNY · Data may be delayed

Company news

Yahoo FinanceMar 30, 2026

AP Biosciences and Tasly Finalize Amended Collaboration Agreement to Support Global Out-Licensing of AP505 (B1962)

TAIPEI, Taiwan, March 30, 2026 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through development of innovative bispecific antibodies, today announced the finalization of an amendment to its development collaboration with Tasly Pharmaceutical Group Co.LTD., establishing a supplementary framework for the anticipated out-licensing of AP505 (B1962) outside the original agreement’s designated Territory (which includes PRC, Hong

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.